The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | The challenges facing elderly AML treatment
To effectively treat acute myeloid leukemia (AML) in elderly patients, it is important that therapies for the right demographic are researched. In this interview, Lars Bullinger, MD, from Charité University of Medicine, Berlin, Germany, discusses the challenges facing the treatment of elderly AML. Prof. Bullinger details how the genomic structure and mutations present in elderly patients produce challenges when developing treatments and how to overcome these issues. This interview was recorded at the International Conference of Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).
